Regulatory FDA renews criticism of trial sponsors over transparency PharmaphorumThe FDA has launched a drive to get clinical trial sponsors to disclose the results of studies - even if they are negative.RegulatoryRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative. RegulatoryRead full story Post navigation Previous: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 UpdateNext: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
